Position in AKBA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$37,769
+$12,058 QoQ
Shares Held
27,172
+70.1% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Gotham Asset Management, LLC holds $203,499,809 across 22 Drug Manufacturers - Specialty & Generic names. AKBA ranks #20 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VTRS |
Viatris Inc
|
4,500,352 | $60,799,755 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
80,387 | $47,667,883 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
360,136 | $47,444,316 | |
| 4 | ZTS |
Zoetis Inc.
|
212,586 | $25,129,791 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
331,032 | $7,921,595 | |
| 6 | BCRX |
Biocryst Pharmaceuticals Inc
|
312,961 | $2,979,388 | |
| 7 | ANIP |
Ani Pharmaceuticals Inc
|
24,095 | $1,852,905 | |
| 8 | COLL |
Collegium Pharmaceutical, Inc
|
55,614 | $1,839,154 |
All Filings in AKBA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $37,769 | 27,172 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $25,711 | 15,970 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $39,582 | 14,499 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $56,671 | 15,569 | Shares | Sole | 2025-08-14 | |
| 2021-06-30 | $72,749 | 19,195 | Shares | Sole | 2021-08-16 | |
| No filing history on record for this holder in this stock. | ||||||